Work

Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline forCYP2D6genotype and use of ondansetron and tropisetron

Year: 2016
Type: article
Abstract: 5-hydroxytryptamine type 3 (5-HT(3)) receptor antagonists are used in the prevention of chemotherapy- induced, radiation-induced and postoperative nausea and vomiting. CYP2D6 polymorphisms can influence the metabolism of some of these drugs (i.e. ondansetron and tropisetron) thereby affecting drug efficacy. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for ondansetron and tropisetron based on CYP2D6 genotype (updates at www.pharmgkb.org).
Language: English
Subfield: Pharmacology
Open Access status: bronze
OpenAlex ID: W2563534429
FWCI: 10.8
Cites: 27
Cited by: 223
Related to: 9